Tech Company Financing Transactions

Atara Biotherapeutics Funding Round

On 12/18/2013, Atara Biotherapeutics raised $38.5 million in Series B investment from Alexandria Venture Investments, Amgen Ventures and Celgene.

Transaction Overview

Announced On
12/18/2013
Transaction Type
Venture Equity
Amount
$38,500,000
Round
Series B
Proceeds Purpose
Proceeds will be used to accelerate the clinical development of Atara's two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
611 Gateway Blvd. 900
San Francisco, CA 94080
USA
Email Address
Overview
Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases.
Profile
Atara Biotherapeutics LinkedIn Company Profile
Social Media
Atara Biotherapeutics Company Twitter Account
Company News
Atara Biotherapeutics News
Facebook
Atara Biotherapeutics on Facebook
YouTube
Atara Biotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Pascal Touchon
  Pascal Touchon LinkedIn Profile  Pascal Touchon Twitter Account  Pascal Touchon News  Pascal Touchon on Facebook
Chief Financial Officer
Utpal Koppikar
  Utpal Koppikar LinkedIn Profile  Utpal Koppikar Twitter Account  Utpal Koppikar News  Utpal Koppikar on Facebook
Chief Medical Officer
AJ Joshi
  AJ Joshi LinkedIn Profile  AJ Joshi Twitter Account  AJ Joshi News  AJ Joshi on Facebook
Chief Scientific Officer
Christopher Haqq
  Christopher Haqq LinkedIn Profile  Christopher Haqq Twitter Account  Christopher Haqq News  Christopher Haqq on Facebook
Chief Technical Officer
Joe Newell
  Joe Newell LinkedIn Profile  Joe Newell Twitter Account  Joe Newell News  Joe Newell on Facebook
VP - Human Resources
Steve Bertram
  Steve Bertram LinkedIn Profile  Steve Bertram Twitter Account  Steve Bertram News  Steve Bertram on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/18/2013: Ginzametrics venture capital transaction
Next: 12/18/2013: WyzAnt venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary